Do you want to read an article? Please log in or register.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Lipid-Lowering Drugs
RECOMMENDED
Related content
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study
Circulation.
Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman DM, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA
doi: 10.1161/CIRCULATIONAHA.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Statins for children with familial hypercholesterolemia
Cochrane Database Syst Rev.
Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U
doi: 10.1002/14651858.
RECOMMENDED
Lipid-Lowering Drugs
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Coll Cardiol
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP, ORION Phase III Investigators.
doi: 10.1016/j.jacc.2020.12.058
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
Int J Cardiol.
Dufour R, Bergeron J, Gaudet D, Weiss R, Hovingh GK, Qing Z, Yang F, Andisik M, Torri A, Pordy R, Gipe DA
doi: 10.1016/j.ijcard.2016.11.046.
RECOMMENDED
Lipid-Lowering Drugs
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Atherosclerosis.
Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR
doi: 10.1016/j.atherosclerosis.
COMMENTED
Heart, Artery and Coronary Diseases
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action
★ 3
Recommended and commented by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1001/jamacardio.2019.5173.
Heart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
J Clin Lipidol.
Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJ.
doi: 10.1016/j.jacl.2016.04.013.
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
Atherosclerosis.
Ramaswami U, Futema M, Bogsrud MP, Holven KB, Roeters van Lennep J, Wiegman A, Descamps OS, Vrablik M, Freiberger T, Dieplinger H, Greber-Platzer S, Hanauer-Mader G, Bourbon M, Drogari E, Humphries SE
doi: 10.1016/j.atherosclerosis.2019.11.012.
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Atherosclerosis.
Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L
doi: 10.1016/j.atherosclerosis.2020.07.006.